Reports Q2 revenue $3.6B, consensus $1.07M. “In Q2, the Carisma team successfully achieved the important clinical milestone of dosing the first patient in the Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA, which represents the next step in our progression of engineering macrophages for the treatment of solid tumors,” said Steven Kelly, CEO. “We continue to execute on our overall strategic plan and we are excited to use this momentum to reach our upcoming potential value inflection points within our HER2 franchise and across our pipeline. We believe we are well-positioned to drive innovation as the leader in engineered macrophages and deliver value to our stakeholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CARM:
- Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Carisma Therapeutics initiated with an Outperform at Evercore ISI
- Carisma announces first patient dosed in Phase I clinical trial of CT-0508
- Carisma to be added to Russell 2000, Russell 3000, and Russell Microcap